Severe Persistent Asthma

Respiratory
2
Pipeline Programs
2
Companies
8
Clinical Trials
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
1
0
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
1100%
+ 1 programs with unclassified modality

On Market (1)

Approved therapies currently available

Teva
CINQAIRApproved
reslizumab
Teva
Interleukin-5 Antagonist [EPC]injection2016

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Teva
TevaIsrael - Petach Tikva
1 program
1
1
ReslizumabPhase 2/3Monoclonal Antibody5 trials
Active Trials
NCT04710134Completed10Est. Jan 2024
NCT03074942Completed30Est. Apr 2018
NCT03052725Terminated391Est. Feb 2018
+2 more trials
Roche
RocheSTAVANGER NORWAY, Norway
1 program
Biomarker based adjustment of corticosteroid doseN/A1 trial
Active Trials
NCT02717689Completed300Est. Jun 2019

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
TevaReslizumab
TevaReslizumab
TevaReslizumab
TevaReslizumab
TevaReslizumab
TevaReslizumab
TevaReslizumab
RocheBiomarker based adjustment of corticosteroid dose

Clinical Trials (8)

Total enrollment: 1,358 patients across 8 trials

NCT04710134TevaReslizumab

Efficacy of Reslizumab Dose Escalation in Patients With Severe Asthma

Start: Feb 2021Est. completion: Jan 202410 patients
Phase 4Completed
NCT03052725TevaReslizumab

A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma

Start: Mar 2017Est. completion: Feb 2018391 patients
Phase 3Terminated
NCT01270464TevaReslizumab

A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma

Start: Feb 2011Est. completion: Sep 2013315 patients
Phase 3Completed
NCT02559791TevaReslizumab

Anti-Interleukin-5 (IL5) Monoclonal Antibody (MAb) in Prednisone-dependent Eosinophilic Asthma

Start: Oct 2015Est. completion: Aug 201710 patients
Phase 2/3Completed
NCT00538434TevaReslizumab

Efficacy and Safety Study of Reslizumab to Treat Eosinophilic Esophagitis in Subjects Aged 5 to 18 Years

Start: Mar 2008Est. completion: Oct 2009227 patients
Phase 2/3Completed
NCT03074942TevaReslizumab

Reslizumab in Patients With Severe Asthma Who Failed to Respond to Omalizumab

Start: Apr 2017Est. completion: Apr 201830 patients
Phase 2Completed
NCT01990443TevaReslizumab

Absolute Bioavailability of Reslizumab in Healthy Subjects

Start: Jun 2013Est. completion: Mar 201475 patients
Phase 1Completed
NCT02717689RocheBiomarker based adjustment of corticosteroid dose

A Pragmatic Trial of Corticosteroid Optimisation in Severe Asthma

Start: Jan 2016Est. completion: Jun 2019300 patients
N/ACompleted

Related Jobs in Respiratory

Regional Gene Therapy Consultant - Upper Midwest (IL/WI/MN)

Krystal Biotech
6m ago
$185K - $215K/yr

Regional Gene Therapy Consultant - Southwest (CO/AZ/NM/UT)

Krystal Biotech
6m ago
$185K - $215K/yr

Marketing Intern – Vertex Iberia (Spain)

Vertex Pharmaceuticals
Madrid, Spain
Yesterday

Sales Rep Neurology Region Leipzig, Halle, Gera, Jena, Weimar DE_G2M110105 - befristet bis 31.03.2027 (all genders)

Sanofi
Berlin
Yesterday

Ausbildung zum Pharmakanten (m/w/d)

Ferring Pharmaceuticals
Kiel, Germany
Yesterday

Laboratory Assistant (m/w/d)

Ferring Pharmaceuticals
Kiel, Germany
2d ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 companies competing in this space

Related Indications

Asthma(378)Pulmonary Disease, Chronic Obstructive(263)Chronic Obstructive Pulmonary Disease(123)Idiopathic Pulmonary Fibrosis(90)COPD(74)Chronic Obstructive Pulmonary Disease (COPD)(38)Pulmonary Embolism(27)Respiratory Syncytial Virus Infections(26)Severe Asthma(21)Lung Diseases, Interstitial(19)